Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001388132 | SCV001589003 | pathogenic | Glycogen storage disease, type V | 2023-06-14 | criteria provided, single submitter | clinical testing | This variant is present in population databases (no rsID available, gnomAD 0.006%). This sequence change creates a premature translational stop signal (p.Val788Alafs*14) in the PYGM gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 55 amino acid(s) of the PYGM protein. This variant has not been reported in the literature in individuals affected with PYGM-related conditions. For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the PYGM protein in which other variant(s) (p.Glu797Valfs*18) have been determined to be pathogenic (PMID: 17630210, 17994553, 19251976, 19472443, 21802952, 22250184). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 1074725). |
Baylor Genetics | RCV001388132 | SCV004207256 | likely pathogenic | Glycogen storage disease, type V | 2023-07-05 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001388132 | SCV005684054 | likely pathogenic | Glycogen storage disease, type V | 2024-05-06 | criteria provided, single submitter | clinical testing |